Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2021 08:30 ET | Source: Veru Inc.

Veru to Present at the Oppenheimer 31st Annual Healthcare Conference

MIAMI, March 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
March 08, 2021 08:30 ET | Source: Veru Inc.

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast...
March 02, 2021 08:30 ET | Source: Veru Inc.

Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference

MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
March 01, 2021 08:30 ET | Source: Veru Inc.

Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)

– Veru completes expedited end of Phase 2 trial meeting with FDA – – FDA agrees that Phase 2 clinical findings suggest a clinically meaningful benefit for the use of VERU-111 in hospitalized COVID-19...
February 23, 2021 08:30 ET | Source: Veru Inc.

Veru Submits New Drug Application for Proprietary TADFIN for BPH

--TADFIN™, Tadalafil 5mg and Finasteride 5mg formulated capsule, for daily oral dosing to improve compliance-- --Administration of Tadalafil and Finasteride is more effective than Finasteride alone...
February 17, 2021 21:30 ET | Source: Veru Inc.

Veru Announces Pricing of Public Offering of Common Stock

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
February 17, 2021 16:01 ET | Source: Veru Inc.

Veru Announces Proposed Public Offering of Common Stock

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...
February 10, 2021 06:30 ET | Source: Veru Inc.

Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter

--Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter-- --Late Clinical Stage Oncology Drug Pipeline Focused on Prostate...
February 08, 2021 07:30 ET | Source: Veru Inc.

Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

– Potential for two-pronged action against COVID-19 as an antiviral and anti-inflammatory agent supported by Phase 2 clinical study results – – Primary efficacy endpoint in...
January 27, 2021 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10th

MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer,...